Lenabasum for Systemic Sclerosis-Are Cannabinoids the Missing Link? Comment on the Article by Spiera et al
- PMID: 33164286
- DOI: 10.1002/art.41578
Lenabasum for Systemic Sclerosis-Are Cannabinoids the Missing Link? Comment on the Article by Spiera et al
Comment in
-
Reply.Arthritis Rheumatol. 2021 Apr;73(4):716-717. doi: 10.1002/art.41579. Epub 2021 Feb 18. Arthritis Rheumatol. 2021. PMID: 33164325 No abstract available.
Comment on
-
Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis.Arthritis Rheumatol. 2020 Aug;72(8):1350-1360. doi: 10.1002/art.41294. Epub 2020 Jul 17. Arthritis Rheumatol. 2020. PMID: 32336038 Free PMC article. Clinical Trial.
References
-
- Spiera R, Hummers L, Chung L, Frech TM, Domsic R, Hsu V, et al. Safety and efficacy of lenabasum in a phase II, randomized, placebo-controlled trial in adults with systemic sclerosis. Arthritis Rheumatol 2020;72:1350-60.
-
- Spiera R, Hummers L, Chung L, Frech T, Domsic R, Hsu V, et al. Safety and efficacy of lenabasum in an open-label extension of a phase 2 study in diffuse cutaneous systemic sclerosis subjects (DCSSC) [abstract]. Ann Rheum Dis 2019;78 Suppl 2:245.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical